公众号 / 文章腹部泌尿生殖CT

病例332

Case 332.
PubMed 文献 · Radiology · 2024-01-01

65岁男性,肉瘤样肾细胞癌右肾切除后复发,接受最大剂量帕唑帕尼及立体定向体部放疗后行腹部盆腔静脉期增强CT监测,出现腹泻、低氯血症及碱性磷酸酶升高。

要点

  • 肉瘤样肾细胞癌右肾切除后复发,帕唑帕尼治疗中出现腹泻和腹部不适。
  • 静脉期增强CT示下腔静脉旁复发病灶,需结合临床与实验室异常综合评估。
  • 血清总蛋白降低、氯降低、碱性磷酸酶升高,提示可能药物相关毒性或肿瘤进展。

核心结论

  • 病例展示肉瘤样肾细胞癌复发患者在帕唑帕尼和立体定向体部放疗后的监测影像,需关注下腔静脉旁病灶及临床实验室异常。

研究设计与样本

  • 病例报告,单例65岁男性,行腹部盆腔静脉期增强CT监测。

关键影像表现/征象

  • 下腔静脉旁复发病灶,具体影像征象原文未详细描述。

临床应用与阅片要点

  • 对肉瘤样肾细胞癌术后复发患者,静脉期增强CT可用于监测下腔静脉旁病灶。
  • 帕唑帕尼治疗中出现腹泻、腹部不适及低氯血症、碱性磷酸酶升高时,需结合影像评估复发与药物毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrectomy developed recurrent disease adjacent to the inferior vena cava. The patient underwent surveillance imaging 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after completing a 2-month regimen of palliative stereotactic body radiation therapy to the right nephrectomy bed and site of recurrence. (Stereotactic body radiation therapy was initiated 5 months after pazopanib treatment was initiated.) One month after initiating treatment with pazopanib and 6 months before the surveillance imaging, the patient developed diarrhea and required ongoing treatment with loperamide to control symptoms. He denied any fatigue, mouth sores, or extremity pain, but described some abdominal pain and discomfort associated with the diarrhea. He was not experiencing any fevers, and vital signs were normal. White blood cell count was normal at 5100/μL (5.1 ×109/L) (normal range, 4200-10 200/μL [4.2-10.2 ×109/L]), with all components of the differential count also being normal. A normal serum albumin level of 3.9 g/dL (39 g/L) (normal range, 3.5-5.0 g/dL [35-50 g/L]) and low serum total protein level of 6.1 g/dL (61 g/L) (normal range, 6.3-7.9 g/dL [63-79 g/L]) were noted. A comprehensive metabolic panel was performed, indicating a serum chloride level of 98 mmol/L (normal, 100-108 mmol/L) and alkaline phosphatase level of 121 U/L (2.02 μkat/L) (normal, 45-115 U/L [0.75-1.92 μkat/L]). The patient underwent surveillance imaging with contrast-enhanced CT of the abdomen and pelvis in the venous phase (Figure).

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Adler C, Menias C. Case 332. Radiology. 2024. PMID: 39189900. doi:10.1148/radiol.232149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。